Market closedNon-fractionalADR
Legend Biotech/LEGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Legend Biotech
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Ticker
LEGN
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
Headquarters
Somerset, United States
Employees
1,800
Website
investors.legendbiotech.com
Legend Biotech Metrics
BasicAdvanced
$7.3B
Market cap
-
P/E ratio
-$2.60
EPS
0.09
Beta
-
Dividend rate
Price and volume
Market cap
$7.3B
Beta
0.09
52-week high
$77.32
52-week low
$39.13
Average daily volume
23
Financial strength
Current ratio
5.663
Quick ratio
5.574
Long term debt to equity
28.484
Total debt to equity
28.752
Interest coverage (TTM)
-24.44%
Management effectiveness
Return on assets (TTM)
-31.22%
Return on equity (TTM)
-51.28%
Return on investment (TTM)
-37.33%
Valuation
Price to revenue (TTM)
21.275
Price to book
6.265
Price to tangible book (TTM)
6.282
Growth
Revenue change (TTM)
231.84%
Earnings per share change (TTM)
20.52%
3-year revenue growth (CAGR)
56.08%
What the Analysts think about Legend Biotech
Analyst Ratings
Majority rating from 22 analysts.
Legend Biotech Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$94M
18.26%
Net income
-$60M
-58.77%
Profit margin
-63.57%
-65.14%
Legend Biotech Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q3 22
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-
-$1.14
-$0.34
-$0.80
-$0.32
Expected
-$0.40
-$0.60
-$0.68
-$0.83
-$0.34
Surprise
-
90.00%
-49.82%
-3.61%
-7.05%
Legend Biotech News
AllArticlesVideos
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024
GlobeNewsWire·14 hours ago
Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results
GlobeNewsWire·2 weeks ago
Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractionalADR
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Legend Biotech stock?
Legend Biotech (LEGN) has a market cap of $7.3B as of July 27, 2024.
What is the P/E ratio for Legend Biotech stock?
The price to earnings (P/E) ratio for Legend Biotech (LEGN) stock is 0 as of July 27, 2024.
Does Legend Biotech stock pay dividends?
No, Legend Biotech (LEGN) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Legend Biotech dividend payment date?
Legend Biotech (LEGN) stock does not pay dividends to its shareholders.
What is the beta indicator for Legend Biotech?
Legend Biotech (LEGN) has a beta rating of 0.09. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Legend Biotech stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.